Please login to the form below

Not currently logged in
Email:
Password:

ozanimod

This page shows the latest ozanimod news and features for those working in and with pharma, biotech and healthcare.

FDA turns down Celgene’s filing for multiple sclerosis drug

FDA turns down Celgene’s filing for multiple sclerosis drug

Celgene is facing a delay for its multiple sclerosis candidate ozanimod in the US and elsewhere as the FDA has refused to accept its marketing application for the drug. ... The embarrassing setback has arisen because of deficiencies in the “nonclinical

Latest news

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Pharma deals in July 2015 Pharma deals in July 2015

    Celgene believes Receptos's ozanimod in phase III for ulcerative colitis could reach peak sales of $4bn to $6bn per year. ... Receptos / Celgene. Company acquisition. Ozanimod in Phase 3 for auto-immune disease.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics